Europe — EMA

Oncotice (Bacillus Calmette-Guérin (Bcg), Tice)

Bacillus Calmette-Guérin (BCG), the active ingredient in Oncotice, is a live attenuated bacterial immunotherapy presented as a suspension for intravesical use.

Bacillus Calmette-Guérin (Bcg), Tice

Request sourcing

Pack/s

What is Bacillus Calmette-Guérin (Bcg), Tice?

Bacillus Calmette-Guérin (BCG), the active ingredient in Oncotice, is a live attenuated bacterial immunotherapy presented as a suspension for intravesical use. It is employed in the treatment of non‑muscle‑invasive bladder cancer, primarily in patients who have undergone transurethral resection of the tumour.

GNH USA supplies Oncotice as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

What is Bacillus Calmette-Guérin (Bcg), Tice used for?

Oncotice is a BCG‑based immunotherapy that acts on the urothelial carcinoma pathway. - Non‑muscle‑invasive bladder cancer: helps the to the tumour re‑ re re re re ... - Carcinoma .... - ... - … - …

What are the side effects of Bacillus Calmette-Guérin (Bcg), Tice?

The ...

Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.

Send a sourcing enquiry for this product →